Table 1.
Candidate targets of EBF activity
| Gene name | Function | FC1 (microarray) |
FC2 (RT-QPCR) |
GenBank |
|---|---|---|---|---|
| pcdh8 | Transmembrane protein | 66 | 93a | BC074360 |
| nr2f2 | Nuclear receptor TF | 47 | ND | BC078057 |
| wnt3a | Wnt signaling ligand | 45 | ND | L07538 |
| peripherin | Type III intermediate filament | 37 | 32a | BC056020 |
| greb1 | Estrogen-regulated gene | 32 | 21b | BC043838 |
| hoxd10 | Homeodomain TF | 31 | ND | BC061944 |
| nf-m | Type IV intermediate filament | 28 | 29b | BC078128 |
| kcnk5 | K+ ion channel | 27 | 6b | BC084931 |
| nscl-1 | bHLH TF | 26 | 7b | BC084434 |
| neurod | bHLH TF | 26 | 164b | BC072996 |
| en-2 | Homeodomain TF | 24 | ND | X62974 |
| aml1 | Runt-related TF | 22 | 24a | BC057739 |
| activin beta b | TGF-beta superfamily member | 21 | 154b | S61773 |
| emx1 | Homeodomain TF | 16 | 15b | BC077629 |
The genes chosen for analysis are shown with their known functional roles. FC1 refers to the average fold change in expression by microarray analysis after DEX treatment for 4.5 hours compared to control, in four replicate experiments. FC2 refers to the fold change in expression after DEX treatment for 3 hours compared to control, as detected by RT-QPCR using independent samples (see Figure 6 and Additional file 6 for details). aPerformed three replicate experiments; bperformed once. FC, fold change; ND, not determined; TF, transcription factor.